PureCycle Technologies Option Alert: Mar 21 $7 Calls Sweep (5) near the Bid: 1776 vs 103 OI; Earnings 2/27 Before Open 

PureCycle Technologies Option Alert: Mar 21 $7 Calls Sweep (5) near the Bid: 1776 @ $3.95 vs 103 OI; Earnings 2/27 Before Open Ref=$10.9

PureCycle Technologies 주식 (NASDAQ: PCT)

PureCycle Technologies (NASDAQ:PCT) 주식

PURECYCLE TECHNOLOGIES INC

PureCycle Technologies

PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.

Mid Cap

News

Movers

Trading Ideas

$BTC

IBRX

IONQ

IRTC

WULF

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:IBRX)의 주식은 회사가 재발성 B-세포 비호지킨 림프종에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.

트럼프 미디어와 스트라이드는 지난주 최고 성과를 보여준 10개 중형주 중 일부 (10월 21일-10월 25일)

PureCycle Technologies, Inc. - Common stock

PureCycle Technologies Inc

PACT GROUP HLDGS UNSP/ADR by Pact Group Holdings Ltd

Pact Group Holdings Ltd

PCTEL Inc

PCT Ltd

PICTON PPTY INCOME LTD by Picton Ppty Income Ltd.

Paylocity Holding Corporation - Common Stock

Paylocity Holding Corp

BRAVERN VENTURES LTD by Bravern Ventures Ltd

Bravern Ventures Ltd

Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.18) by 72.22 percent. This is a 47.62 percent decrease over losses of $(0.21) per share from the same period last year.

Earnings

Earnings Misses

MIST

Milestone Pharmaceuticals Q1 EPS $(0.31) Misses $(0.18) Estimate

Climb Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLYM#NASDAQ">CLYM</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.15) by 106.67 percent. This is a 416.67 percent decrease over losses of $(0.06) per share from the same period last year.

CLYM

Climb Bio Q1 EPS $(0.31) Misses $(0.15) Estimate

Benchmark analyst Cody Acree reiterates Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Buy and maintains $160 price target.

Price Target

Reiteration

Analyst Ratings

SLAB

Benchmark Reiterates Buy on Silicon Laboratories, Maintains $160 Price Target

SRRK

Scholar Rock Holding Q1 EPS $(0.67) Misses $(0.65) Estimate

Live Nation To Anchor New 5,300-Seat Venue at Atlanta's $5B Centennial Yards District

DAVA

Endava And AlixPartners Form Strategic Partnership To Deliver End-To-End Technology-Driven Solutions And Accelerate Digital Transformation Globally

Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 49.15 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $5.95 million which beat the analyst consensus estimate of $5.82 million by 2.34 percent. This is a 17.86 percent increase over sales of $5.05 million the same period last year.

Earnings Beats

FHTX

Foghorn Therapeutics Q1 EPS $(0.30) Beats $(0.31) Estimate, Sales $5.95M Beat $5.82M Estimate

MRCY

Mercury Launches ROCK3 Mission Computer To Power AI, 5G-Enabled Military And Urban Air Platforms

WIIM

SEPN

Septerna shares are trading higher after the company announced an exclusive global collaboration and license agreement with Novo Nordisk to develop oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases.

Radcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDCM#NASDAQ">RDCM</a>) raises FY2025 sales outlook from $69.20 million to $71.10 million vs $68.75 million estimate.

Guidance

RDCM

Radcom Raises FY2025 Sales Guidance from $69.20M to $71.10M vs $68.75M Est

CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 3700 percent decrease over earnings of $0.01 per share from the same period last year.

CALC

CalciMedica Q1 EPS $(0.36) Misses $(0.31) Estimate

Aeluma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMU#NASDAQ">ALMU</a>), a semiconductor company specializing in high-performance, scalable technologies for mobile, automotive, AI, defense and aerospace, communication, and quantum computing, announced today it will participate in two key upcoming industry conferences: the 2025 International Conference on Compound Semiconductor Manufacturing Technology (CS Mantech) and the 2025 IEEE Optical Interconnects and Packaging Conference (OIP).
At the conferences, Aeluma will present technical advancements in shortwave infrared photodetectors, high-speed optical interconnects, and quantum dot lasers for silicon photonics, core technologies engineered to meet the growing performance and scale requirements of AI infrastructure, quantum, and sensing systems.
At <a href="https://pr.report/ae75">CS Mantech</a>, being held May 19-22, 2025 in New Orleans, Louisiana, Aeluma will deliver a talk titled: "Heterogeneous Integration of Large-Area InGaAs SWIR Photodetectors on 300mm CMOS-Compatible Si Substrates." This session will spotlight Aeluma's novel approach to wafer-scale manufacturing of high-performance photodetector arrays enabling compact, energy-efficient solutions for mobile and consumer, AR/VR, defense and aerospace, and industrial automation.
At the <a href="https://pr.report/ae76">IEEE OIP</a>, being held June 16-18, 2025 in Fort Collins, Colorado, Aeluma will present:
"Heterogeneous Integration of InGaAs PIN and APD Photodetectors for High-Speed Interconnects," focusing on data center, AI infrastructure, and aerial systems.
"Scalable and Monolithic Integration of Quantum Dot Lasers for Silicon Photonics," addressing critical bottlenecks in next-generation optical interconnects, AI infrastructure, quantum, and sensing.

ALMU

Aeluma to Showcase Breakthrough AI and Quantum Tech at Key Semiconductor Conferences

Telsey Advisory Group analyst Dana Telsey maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Market Perform and lowers the price target from $27 to $17.

Telsey Advisory Group Maintains Market Perform on VF, Lowers Price Target to $17

Toyota Adds 20th Electrified Model With 2026 C-HR BEV: High Power, Long Range, Striking Looks

BRKR

Bruker And 10x Genomics Settle Patent Disputes And Enter Global Cross-License Agreement, Dismissing All Ongoing Litigations

Needham analyst Charles Shi maintains Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) with a Buy and lowers the price target from $110 to $80.

CAMT

Needham Maintains Buy on Camtek, Lowers Price Target to $80

Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.67) by 47.76 percent. This is a 40.68 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $32.98 million which beat the analyst consensus estimate of $9.38 million by 251.72 percent. This is a 479.03 percent increase over sales of $5.70 million the same period last year.

VERV

Verve Therapeutics Q1 EPS $(0.35) Versus $(0.59) YoY, Sales $32.98M

AVEA

Aeva Inks Strategic Collaboration With Global Tech Affiliate, Secures Up To $50M Investment Including Equity Stake

EDIT

Editas Medicine Unveils New In Vivo Data Highlighting Potential of Editas' Gene Upregulation Strategy In HSCs At American Society of Gene and Cell Therapy Annual Meeting

Health Care

General

TECH

ScaleReady, In Collaboration With Wilson Wolf Manufacturing, Bio-Techne And CellReady Announced Three G-rex Grants That Have Been Awarded To Faculty Members At The University Of Southern California And The Children's Hospital Of Los Angeles. The Funding Totaling $1.025M Will Support The Translation Of Various Cell And Gene Therapy Initiatives Into The Clinic

Press Releases

Churchill Introduces "Run It Back" Line of Cups & Containers Made with Recycled PureFive(TM) Resin

PureCycle Schedules Fourth Quarter 2024 Corporate Update

PureCycle Technologies Fourth Quarter and Fiscal Year Ending 2024 Update

PureCycle Announces Preliminary Court Approval of Shareholder Derivative Settlement

PureCycle and Landbell Group Collaborate to Advance Polypropylene Plastic Recycling in Europe

PureCycle Announces Sale of Approximately $30 Million in Revenue Bonds

PureCycle Schedules First Quarter 2025 Corporate Update

PureCycle Provides Update on BOPP Film Trials

PureCycle Invites Ironton and Denver Communities to Tour Recycling Facilities

PureCycle Technologies First Quarter 2025 Corporate Update

AdvanSix

Braskem

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings

Cabot

Core Molding Technologies Inc Common Stock

Core Molding Technologies

CN Energy Group Inc. - Class A Ordinary Shares

CN Energy Group

Gulf Resources

Hawkins

Koppers Holdings

Kronos Worldwide

Loop Industries

Mativ Holdings

Orion

Olin

Origin Materials, Inc. - Class A Common Stock

Origin Materials

Tronox Holdings

Trinseo

Westlake

Westlake Chemical Partners LP Common Units representing limited partner interests

Comments

PureCycle Technologies

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌